Lebrikizumab Biosimilar - Research Grade

Human

IL-13

>1mg/ml

Human IgG4 S228P Kappa

Tralokinumab Biosimilar - Research Grade (ICH5059), Abrezekimab Biosimilar - Research Grade (ICH5324), Anrukinzumab Biosimilar - Research Grade (ICH5347), Cendakimab Biosimilar - Research Grade (ICH5432), Dectrekumab Biosimilar - Research Grade (ICH5470)

https://www.imgt.org/mAb-DB/

ICH3002

P35225

3596

RRID:AB_2921600

Blue ice

This product is a research-grade biosimilar of lebrikizumab: an unconjugated, non-therapeutic recombinant human IgG4 (S228P) kappa antibody engineered to recognise human interleukin-13 (IL-13). It is not the clinical drug and is intended for research use only, not for human or veterinary application. Supplied unconjugated with low endotoxin (research grade less than 1 EU/mg; ultra-low grade less than 0.5 EU/mg) and available in bulk milligram-to-gram quantities, it is suited to laboratory workflows that require a well-defined, consistent anti-IL-13 reagent. Typical research applications include use as a functional positive control or benchmark in IL-13 binding and neutralisation assays, characterisation of IL-13/receptor signalling in vitro, epitope and affinity comparison studies, assay development and standardisation, and as a comparator molecule in preclinical antibody discovery and biosimilarity programmes. The S228P hinge stabilisation reduces IgG4 half-antibody exchange, giving a more homogeneous reagent for reproducible experiments. It lets researchers interrogate IL-13-driven biology without sourcing clinical material. Interleukin-13 (IL-13; UniProt P35225) is a roughly 13 kDa four-helix-bundle cytokine produced mainly by activated Th2 lymphocytes, mast cells, basophils, eosinophils and ILC2 cells. It is a central effector of type 2 immunity and shares many activities with IL-4. IL-13 signals through a receptor system comprising IL-13Ralpha1, which pairs with IL-4Ralpha to form the type II receptor that activates JAK/STAT6 signalling, and the high-affinity decoy receptor IL-13Ralpha2, which sequesters IL-13. Downstream effects include IgE class switching, goblet-cell mucus production, smooth-muscle hyperresponsiveness, eosinophil recruitment, fibroblast activation and tissue remodelling. Dysregulated IL-13 is strongly implicated in asthma, atopic dermatitis and other allergic and fibrotic conditions, making it a validated therapeutic and research target.

Interleukin-13, NC30

Detects human IL-13. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Lebrikizumab.

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

S228P

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Lebrikizumab (anti-IL-13) Biosimilar

Q: Is the Lebrikizumab biosimilar available in gram quantities?

A: Yes — it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: Is this research-grade Lebrikizumab suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Lebrikizumab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Lebrikizumab that binds human IL-13.